芦可替尼治疗骨髓纤维化和真性红细胞增多症 - Suppr

Ruxolitinib in Myelofibrosis and Polycythemia Vera.

作者信息

Wolfe Leah

机构信息

Hematology Oncology Center Inc. - Pharmacy, Elyria, Ohio.

出版信息

J Adv Pract Oncol. 2016 May-Jun;7(4):436-444. Epub 2016 May 1.

PMID:29226001

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5679032/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c3d/5679032/720f3c27f226/jadp-07-436-g01.jpg

相似文献

Ruxolitinib in Myelofibrosis and Polycythemia Vera.

J Adv Pract Oncol. 2016 May-Jun;7(4):436-444. Epub 2016 May 1.

Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation.

Clin Case Rep. 2021 Sep 5;9(9):e04782. doi: 10.1002/ccr3.4782. eCollection 2021 Sep.

Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib.

Infect Drug Resist. 2020 Apr 8;13:1017-1021. doi: 10.2147/IDR.S249030. eCollection 2020.

Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.

Arch Pathol Lab Med. 2014 Sep;138(9):1203-9. doi: 10.5858/arpa.2013-0018-OA.

Contemporary approach to essential thrombocythemia and polycythemia vera.

Curr Opin Hematol. 2016 Mar;23(2):150-60. doi: 10.1097/MOH.0000000000000216.

Janus kinase inhibitors: jackpot or potluck?

Oncol Rev. 2012 Jun 20;6(1):e13. doi: 10.4081/oncol.2012.e13. eCollection 2012 Mar 5.

Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.

Nat Immun. 1993 May-Jun;12(3):136-51.

Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement.

Wien Klin Wochenschr. 2017 May;129(9-10):293-302. doi: 10.1007/s00508-016-1120-8. Epub 2016 Dec 13.

Neutropenia caused by hairy cell leukemia in a patient with myelofibrosis secondary to polycythemia vera: a case report.

J Med Case Rep. 2018 Apr 24;12(1):105. doi: 10.1186/s13256-018-1663-6.

Austrian recommendations for the management of polycythemia vera.

Wien Klin Wochenschr. 2018 Sep;130(17-18):535-542. doi: 10.1007/s00508-018-1359-3. Epub 2018 Jul 19.

引用本文的文献

Selective Inhibitors of Janus Kinase 3 Modify Responses to Lipopolysaccharides by Increasing the Interleukin-10-to-Tumor Necrosis Factor α Ratio.

ACS Pharmacol Transl Sci. 2023 May 18;6(6):892-906. doi: 10.1021/acsptsci.3c00043. eCollection 2023 Jun 9.

The development of COVID-19 treatment.

Front Immunol. 2023 Jan 26;14:1125246. doi: 10.3389/fimmu.2023.1125246. eCollection 2023.

Pharmacokinetic Optimization of Small Molecule Janus Kinase 3 Inhibitors to Target Immune Cells.

ACS Pharmacol Transl Sci. 2022 Jul 14;5(8):573-602. doi: 10.1021/acsptsci.2c00054. eCollection 2022 Aug 12.

Binding of the small-molecule kinase inhibitor ruxolitinib to membranes does not disturb membrane integrity.

Biochem Biophys Rep. 2020 Nov 2;24:100838. doi: 10.1016/j.bbrep.2020.100838. eCollection 2020 Dec.

Hi--ng Synovial Fibroblasts in Inflammatory Arthritis With JAK Inhibitors.

Front Med (Lausanne). 2020 May 5;7:124. doi: 10.3389/fmed.2020.00124. eCollection 2020.

Block-And-Lock Strategies to Cure HIV Infection.

Viruses. 2020 Jan 10;12(1):84. doi: 10.3390/v12010084.

Efficacy of JAK inhibitors in Crohn's Disease.

J Crohns Colitis. 2020 Aug 1;14(Supplement_2):S746-S754. doi: 10.1093/ecco-jcc/jjz186.

本文引用的文献

Diagnosis and Management of Polycythemia Vera: Proceedings from a Multidisciplinary Roundtable.

Am Health Drug Benefits. 2014 Oct;7(7 Suppl 3):S36-47.

The need for United States-based guidelines for myeloproliferative neoplasms.

J Natl Compr Canc Netw. 2015 May;13(5):607-9. doi: 10.6004/jnccn.2015.0078.

Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.

J Natl Compr Canc Netw. 2015 Apr;13(4):424-34. doi: 10.6004/jnccn.2015.0058.

Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

N Engl J Med. 2015 Jan 29;372(5):426-35. doi: 10.1056/NEJMoa1409002.

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.

Haematologica. 2015 Apr;100(4):479-88. doi: 10.3324/haematol.2014.115840. Epub 2015 Jan 23.

Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.

Am J Hematol. 2015 Feb;90(2):162-73. doi: 10.1002/ajh.23895.

Optimizing the management of patients with myelofibrosis.

Clin J Oncol Nurs. 2014 Jun;18(3):330-7. doi: 10.1188/14.CJON.330-337.

Ruxolitinib for the treatment of primary myelofibrosis.

Am J Health Syst Pharm. 2014 Mar 15;71(6):453-62. doi: 10.2146/ajhp120602.

Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application.

Biomark Res. 2013 Jan 16;1(1):5. doi: 10.1186/2050-7771-1-5.

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.

Blood. 2013 Dec 12;122(25):4047-53. doi: 10.1182/blood-2013-02-485888. Epub 2013 Oct 30.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Ruxolitinib in Myelofibrosis and Polycythemia Vera.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献